Merck’s Harpoon acquisition deepens oncology pipeline ahead of Keytruda risk

Merck's Harpoon acquisition deepens oncology pipeline ahead of Keytruda risk

Merck has completed its acquisition of Harpoon Therapeutics, adding an immuno-oncology company to its pipeline as it keeps building beyond Keytruda. For analysts and BD teams, the deal is a signal to watch for follow-on M&A and pipeline diversification.

IntelligenceRegulatory Impact▾

FDA and EMA decisions frame this story. Regulatory relevance is medium for oncology, with Keytruda most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.

Key Takeaways

• Merck has completed the acquisition of Harpoon Therapeutics, Inc., an immuno-oncology company now wholly owned by Merck.
• The transaction represents Merck's continued use of external innovation to diversify its oncology exposure, with Keytruda operating as a programmed death receptor-1 (PD-1)-blocking antibody in its current portfolio.
• BD and investor teams should track whether Merck sustains this M&A cadence, particularly following the $6.7 billion Terns Pharma acquisition announced in March 2026.

IntelligenceCompetitive Intelligence▾

Competitive pressure is high. Merck & Co., Harpoon Therapeutics, and Terns Pharma reshape positioning, formulary leverage, and partnership options. Benchmark pipeline differentiation and regional market access assumptions against this development.

Merck completes the Harpoon Therapeutics acquisition

Merck has completed the acquisition of Harpoon Therapeutics, Inc., bringing the immuno-oncology company into its portfolio as a wholly-owned subsidiary. Harpoon, an immuno-oncology developer founded by Patrick Baeuerle, PhD, and MPM Capital, now operates under Merck's ownership.

The acquisition underscores Merck's strategy to build pipeline depth in oncology through targeted M&A. Rather than a bet on a single asset, the deal reflects a portfolio-building approach designed to hedge against competitive and revenue pressure in the immuno-oncology space.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance medium for oncology. Expect implications for pricing, access, and launch sequencing.

Why the deal matters for Merck's oncology strategy

To strengthen its oncology portfolio, Merck has adopted a strategy of acquiring clinical-stage and preclinical oncology companies to broaden its pipeline. The Harpoon transaction fits that pattern.

This is not Merck's only recent bet. Merck announced on March 25, 2026, that it would buy biotech firm Terns Pharma for $6.7 billion, a much larger transaction aimed at bolstering its cancer pipeline. For BD teams and investors, the cadence of deals signals that Merck views M&A as a core lever for portfolio building in oncology.

IntelligenceStrategic Takeaways▾

Merck has completed the acquisition of Harpoon Therapeutics, Inc. , an immuno-oncology company now wholly owned by Merck. The transaction represents Merck's continued use of external innovation to diversify its oncology exposure, with Keytruda operating as a programmed death receptor-1 (PD-1)-blocking antibody in its current portfolio. BD and investor teams should track whether Merck sustains this M&A cadence, partic

What Harpoon adds to the pipeline

Harpoon is an immuno-oncology company focused on the T-cell engaging therapy space, an area pioneered by co-founder Patrick Baeuerle, PhD. The specific details of Harpoon's clinical pipeline and development stage have not been disclosed in available sources. Search interest around "Hpn328 merck" and "Harpoon therapeutics pipeline" suggests investor and analyst attention to Harpoon's asset portfolio, but the evidence does not contain specific program names, development stages, or trial identifiers tied to Harpoon's assets.

Merck has not yet disclosed detailed integration plans or pipeline prioritization for Harpoon programs following the acquisition close.

IntelligenceEvidence Quality▾

Grounded in 1 regulatory source.

Clinical evidence and ongoing trial readouts to monitor

The immuno-oncology space continues to see active clinical investigation across multiple disease areas. Several recruiting trials demonstrate ongoing research in pembrolizumab-based and related approaches:

NCT07353957 is a Phase 2 trial investigating petosemtamab in adults with metastatic non-small cell lung cancer. NCT05232409, a Phase 1 trial, is determining the safety and recommended Phase 2 dosing of zeaxanthin alone or in combination with pembrolizumab in patients with metastatic cancer. NCT07198074, a Phase 3 trial led by the National Cancer Institute, is testing the addition of bevacizumab to chemotherapy and pembrolizumab for pMMR, TP53 mutated endometrial cancer. NCT07276399, another Phase 3 trial, is evaluating amivantamab in addition to standard of care compared with standard of care alone in recurrent or metastatic head and neck cancer.

These trials represent ongoing activity in immuno-oncology development. None of these trials are tied to Harpoon assets in the available evidence.

Investor and competitive implications

The Harpoon transaction reinforces the market expectation that large-cap pharma will continue to pursue pipeline-building M&A in oncology. The follow-on $6.7 billion Terns Pharma acquisition signals that Merck views external innovation as a key element of its oncology strategy.

For BD teams and investors, the pattern of acquisitions underscores the importance of tracking Merck's M&A activity as a bellwether for competitive positioning in immuno-oncology and the broader oncology market.

Frequently Asked Questions

Related profiles

• KEYTRUDA

Related coverage

• FDA approves Keytruda for adjuvant NSCLC treatment, expanding Merck’s lung cancer label
• FDA approves Merck’s Keytruda for adjuvant NSCLC treatment
• FDA approves Keytruda for adjuvant NSCLC, a Merck catalyst